Lithium Ion

Lithium Ion

SCHEMBL2116736

O=C([O-])c1ccc2cc(I)cc(-c3cccc4ccccc34)c2n1.[Li+]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.40
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
GPR84 Q9NQS5 1/20 0.34
KDM4E B2RXH2 3/20 0.34
ALPL P05186 1/20 0.34
GAA P10253 1/20 0.34
PIK3CA P42336 1/20 0.33
MCL1 Q07820 1/20 0.33
ACMSD Q8TDX5 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118893 0.87 FDPS (0.52) FDPSKMT2AMEN1GPR84KDM4E
Lithium SCHEMBL2116737 0.86 FDPS (0.51) FDPSKMT2AMEN1GPR84KDM4E
SCHEMBL2116734 0.86 FDPS (0.51) FDPSKMT2AMEN1GPR84KDM4E
SCHEMBL2117118 0.80 KMT2A (0.50) FDPSKMT2AMEN1KDM4EGAA
Lithium Ion SCHEMBL2119062 0.78 PIM1 (0.39) FDPSKMT2AMEN1KDM4EGAA
SCHEMBL2116297 0.76 GPR84 (0.35) FDPSKMT2AMEN1GPR84KDM4E
SCHEMBL13689572 0.76 NCF1 (0.39) FDPSKMT2AMEN1GPR84KDM4E
Lithium Ion SCHEMBL2120920 0.74 FDPS (0.63) FDPSKMT2AMEN1KDM4EALDH1A1
SCHEMBL2117674 0.73 SOS2 (0.43) KMT2AMEN1GPR84KDM4EALPL
SCHEMBL2118027 0.72 FDPS (0.57) FDPSKMT2AMEN1GPR84KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094958-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2012-04-19 US claimed
EP-2250152-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE Novartis AG (CH) 2010-11-17 EP claimed
WO-2009106586-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2009-09-03 WO claimed
US-20120094958-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2012-04-19 US disclosed
EP-2250152-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE Novartis AG (CH) 2010-11-17 EP disclosed
WO-2009106586-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094958-A1 QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE FDPS, GGPS1, CTPS1 FDPS 1/4885KMT2A 3963/4885MEN1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.